Literature DB >> 16581975

Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha.

Krishnan Sriram1, Joanna M Matheson, Stanley A Benkovic, Diane B Miller, Michael I Luster, James P O'Callaghan.   

Abstract

Enhanced expression of tumor necrosis factor (TNF) -alpha, is associated with the neuropathological effects underlying disease-, trauma- and chemically induced neurodegeneration. Previously, we have shown that deficiency of TNF receptors protects against MPTP-induced striatal dopaminergic neurotoxicity, findings suggestive of a role for TNF-alpha in neurodegeneration. Here, we demonstrate that deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP. MPTP-induced expression of microglia-derived factors, TNF-alpha, MCP-1, and IL-1alpha, preceded the degeneration of striatal dopaminergic nerve terminals and astrogliosis, as assessed by loss of striatal dopamine and TH, and an increase in striatal GFAP. Pharmacological neuroprotection with the dopamine reuptake inhibitor, nomifensine, abolished striatal dopaminergic neurotoxicity and associated microglial activation. Similarly, in mice lacking TNF receptors, microglial activation was suppressed, findings consistent with a role for TNF-alpha in striatal MPTP neurotoxicity. In the hippocampus, however, TNF receptor-deficient mice showed exacerbated neuronal damage after MPTP, as evidenced by Fluoro Jade-B staining (to identify degenerating neurons) and decreased microtubule-associated protein-2 (MAP-2) immunoreactivity. These effects were not accompanied by microglial activation, but were associated with increased oxidative stress (nitrosylation of tyrosine residues). These findings suggest that TNF-alpha exerts a neurotrophic/neuroprotective effect in hippocampus. The marked differences we observed in the regional density, distribution and/or activity of microglia and microglia-derived factors may influence the region-specific role for this cell type. Taken together, our results are indicative of a region-specific and dual role for TNF-alpha in the brain: a promoter of neurodegeneration in striatum and a protector against neurodegeneration in hippocampus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16581975     DOI: 10.1096/fj.05-5106com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  101 in total

1.  Testing NF-κB-based therapy in hemiparkinsonian monkeys.

Authors:  Susanta Mondal; Avik Roy; Arundhati Jana; Sankar Ghosh; Jeffrey H Kordower; Kalipada Pahan
Journal:  J Neuroimmune Pharmacol       Date:  2012-06-03       Impact factor: 4.147

2.  Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimer's disease and non-demented patients.

Authors:  Xin Cheng; Libang Yang; Ping He; Rena Li; Yong Shen
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

3.  Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice.

Authors:  David R Beers; Weihua Zhao; Bing Liao; Osamu Kano; Jinghong Wang; Ailing Huang; Stanley H Appel; Jenny S Henkel
Journal:  Brain Behav Immun       Date:  2010-12-19       Impact factor: 7.217

4.  Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.

Authors:  Melissa K McCoy; Terina N Martinez; Kelly A Ruhn; David E Szymkowski; Christine G Smith; Barry R Botterman; Keith E Tansey; Malú G Tansey
Journal:  J Neurosci       Date:  2006-09-13       Impact factor: 6.167

5.  Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration.

Authors:  Liya Qin; Xuefei Wu; Michelle L Block; Yuxin Liu; George R Breese; Jau-Shyong Hong; Darin J Knapp; Fulton T Crews
Journal:  Glia       Date:  2007-04-01       Impact factor: 7.452

6.  Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease.

Authors:  R Pattarini; R J Smeyne; J I Morgan
Journal:  Neuroscience       Date:  2007-01-29       Impact factor: 3.590

Review 7.  Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.

Authors:  Malú G Tansey; Melissa K McCoy; Tamy C Frank-Cannon
Journal:  Exp Neurol       Date:  2007-07-17       Impact factor: 5.330

8.  Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum.

Authors:  R Pattarini; Y Rong; C Qu; J I Morgan
Journal:  Neuroscience       Date:  2008-07-08       Impact factor: 3.590

Review 9.  Neuroinflammation and microglia: considerations and approaches for neurotoxicity assessment.

Authors:  Gaylia Jean Harry; Andrew D Kraft
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-10       Impact factor: 4.481

10.  Oligomeric Aβ-induced microglial activation is possibly mediated by NADPH oxidase.

Authors:  Juan Li; Jing Yu Yang; Xue Chun Yao; Xue Xue; Qing Chun Zhang; Xiao Xiao Wang; Ling Ling Ding; Chun Fu Wu
Journal:  Neurochem Res       Date:  2012-12-11       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.